Egeberg, Alexander http://orcid.org/0000-0001-8257-1816
Conrad, Curdin http://orcid.org/0000-0002-2547-3440
Gorecki, Patricia http://orcid.org/0000-0002-5657-5001
Wegner, Sven http://orcid.org/0000-0002-9510-9310
Buyze, Jozefien http://orcid.org/0000-0001-6780-380X
Acciarri, Lorenzo http://orcid.org/0009-0002-2654-9459
Thaçi, Diamant http://orcid.org/0000-0001-8513-550X
Clinical trials referenced in this document:
Documents that mention this clinical trial
Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials
https://doi.org/10.1007/s13555-024-01123-1
Documents that mention this clinical trial
Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials
https://doi.org/10.1007/s13555-024-01123-1
Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
https://doi.org/10.1007/s13555-023-01012-z
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
https://doi.org/10.1007/s40257-023-00816-1
Article History
Received: 24 January 2024
Accepted: 14 February 2024
First Online: 15 March 2024
Declarations
:
: Alexander Egeberg has received research funding from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, the Danish National Psoriasis Foundation, Eli Lilly, Janssen Pharmaceuticals, the Kgl Hofbundtmager Aage Bang Foundation, Novartis, Pfizer, and the Simon Spies Foundation, and honoraria as consultant or speaker from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Galapagos NV, Galderma, Horizon Therapeutics, Janssen, LEO Pharma, Mylan, Novartis, Pfizer, Samsung Bioepis Co., Ltd., Sun Pharmaceuticals, UCB, Union Therapeutics, and Zuellig Pharma Ltd. Since the completion of this work, Alexander Egeberg has changed affiliation. His new affiliation is LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup, Denmark. Curdin Conrad received research grants or served as a scientific adviser or clinical study investigator for AbbVie, Actelion, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Samsung, Sanofi, and UCB. Jozefien Buyze, Patricia Gorecki, and Sven Wegner are employees of Janssen; Sven Wegner holds stocks in Johnson & Johnson; Lorenzo Acciarri is an employee of Valos Srl, a Johnson & Johnson partner company. Diamant Thaçi has been a consultant, investigator, and speaker and participated in advisory boards for AbbVie, Almirall, Amgen, Biogen Idec, Bristol Myers Squibb, Janssen-Cilag, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Sanofi, and UCB, and has received research/educational grants from AbbVie, LEO Pharma, Novartis, and Sanofi.
: The ECLIPSE and VOYAGE 1 trials were sponsored by Janssen and conducted in accordance with the ethical principles derived from international guidelines, including the Declaration of Helsinki. An institutional review board or ethics committee approved the study protocol at participating sites.